Impact of initial time to prostate-specific antigen nadir on survival in prostate cancer with bone metastasis initially treated with maximum androgen blockade therapy
Journal Title: Journal of Cancer Research & Therapy - Year 2013, Vol 1, Issue 8
Abstract
Background: The objective of this study is to provide certain data on clinical outcomes and their predictors of traditional maximum androgen blockade (MAB) in prostate cancer with bone metastasis. Methods: Subjects were patients with prostate adenocarcinoma with bone metastasis initiated to treat with MAB as a primary treatment without any local therapy at our hospital between January 2003 and December 2010. Time to prostate specific antigen (PSA) progression, overall survival (OS) time, and association of clinical factors and outcomes were retrospectively evaluated. Results: A total of 57 patients were evaluable. The median age was 70 years. The median primary PSA was 203 ng/ml. Luteinizing hormone-releasing hormone agonists had been administered in 96.5% of the patients. Bicalutamide had been chosen in 89.4 % of the patients as the initial antiandrogen. The median time to PSA progression with MAB was 11.3 months (95% confidence interval [CI], 10.4 to 13.0). The median OS was 47.3 months (95% CI, 30.7 to 81.0). Gleason score 9 or greater, decline of PSA level equal to or higher than 1.0 ng/ml with MAB, and time to PSA nadir equal to or shorter than six months after initiation of MAB were independent risk factors for time to PSA progression (P=0.010, P=0.005, and P=0.001; respectively). Time to PSA nadir longer than six months was the only independent predictor for longer OS (HR, 0.255 [95% CI, 0.109 to 0.597]; P=0.002). Conclusions: Initial time to PSA nadir should be emphasized for clinical outcome analyses in future studies on prostate cancer with bone metastasis.
Authors and Affiliations
Yamamoto Y, Nozawa M, Itami Y, Kobayashi Y, Saito Y, Shimizu N, Minami T, Hayashi T, Tsuji H, Yoshimura K, Ishii T, Uemura H
Keywords
Related Articles
- EP ID EP551739
- DOI 10.14312/2052-4994.2013-30
- Views 62
- Downloads 0
Improving patient data quality by integrating oncology practice and state cancer registry tumor staging information: Feasibility and future value
Background: The transition in oncology to electronic charting offers the potential to improve the quality of patient care and value of observational research. Data fields that are more complete, have common standards, an...
Ecological model links proto-oncogene to high incidence of metastatic cancers in African-Americans
Cancers identified by the uncontrolled proliferation of the TRPV6 mRNA biomarker, kill African-Americans (AAs) at nearly twice the rate of Whites. Malignancies assigned to this class include: Metastatic prostate cancer,...
Histopathological investigation of differences between female and male rats on radiation-induced acute lung toxicity
Radiation-induced acute and chronic lung toxicity is one of the important adverse events that has a negative influence on quality of life. It is widely accepted today that there are important factors such as personal sen...
Primary malignant giant cell tumour of the proximal tibia: a case report
Primary malignant giant cell tumour of bone is extremely rare and very few examples exist in the literature. We report a case of a 37-year-old man with a primary malignant giant cell tumour of the proximal tibia. He was...
EYA1 expression and subcellular localization in neuroblastoma and its association with prognostic markers
Neuroblastoma, the most frequently occurring extracranial solid tumor of childhood, arises from neural crest-derived cells that are arrested at an early stage of differentiation in the developing sympathetic nervous syst...